Perspective on key issues
Novartis believes transparency and partnership are key drivers toward finding long-term, sustainable solutions to global health challenges.
To this end, Novartis maintains relationships with key public health stakeholders including government officials, politicians, regulatory authorities, international organizations, nongovernmental organizations and patient groups. We engage in major policy debates, sharing the company’s perspective on public health issues and striving for open and constructive interaction.
As part of our ongoing commitment to transparency, we state our position on various issues affecting our business. Please feel free to contact Public Affairs at:
Download the fact sheets:
Access to medicines in the developing world
(89 KB)
Animal experimentation
(72 KB)
Biodiversity/Bioprospecting
(81 KB)
Competitive off-patent markets
(76 KB)
Counterfeit medicines
(44 KB)
Disclosure of clinical research information
(54 KB)
Ethical promotion of pharmaceuticals
(32 KB)
Genetic testing (Employment)
(97 KB)
Harmonization of HTA methodology and processes
(76 KB)
Health Technology Assessment
(172 KB)
Human rights
(62 KB)
Information to patients
(69 KB)
Naming requirements for Biosimilars
(89 KB)
Nanotechnology-based medicine
(92 KB)
Organ donation
(83 KB)
Patient group interaction and support
(73 KB)
Pharmaceuticals in the environment
(56 KB)
The Right to Health
(231 KB)